The thesis

Two markets that share almost nothing, and solve each other's problem.

United States

Demand without sites

The constraint is not the medicine and not the evidence. It is the licensed site. In July 2026 the FDA approved the leading agent in hormone sensitive metastatic disease, so it can now be used across all stages of PSMA positive metastatic prostate cancer. The manufacturer states this nearly doubles the eligible population. Demand roughly doubled. The number of licensed sites did not.

South Africa

Isotope without delivery

SAFARI-1 at Pelindaba and its commercial arm NTP Radioisotopes supply a very large share of the world's molybdenum-99 and also produce lutetium-177, serving customers in more than sixty countries. The country exports the raw material of nuclear medicine and treats almost none of its own patients with the therapeutic form of it.